PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 244 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour July 25, 2022 Scottish Soccer Star Who Just Announced Breast Cancer Diagnosis Scores Goal,... December 21, 2020 Reunión anual de la American Society of Clinical Oncology (ASCO) de... June 3, 2022 Data Shows Women Are Not Getting Access To An Important Part... July 30, 2021 Load more HOT NEWS Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds How to Talk About Cancer With Someone Who Has It ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure...
